AltaThera is committed to providing therapies that address the costly and complex challenges of adult atrial fibrillation. Our values reflect our commitment to helping providers and hospitals optimize the delivery of quality care.
Adult atrial fibrillation is high stakes in terms of lives and costs. Our goal is to provide products that improve efficiencies when it matters most, like reducing hospital length of stay.
We strive to offer products that can help providers and hospitals administer treatment most effectively, like using an IV option over an oral.
The ultimate measure of any product’s success is its outcome. Excellence in outcomes and an efficient, effective delivery of care make the benefits far reaching for more patients.
Jodi Devlin has 30 years of pharmaceutical experience. She has held executive-level roles at large pharmaceutical companies and start-ups. Her expertise spans Abbott /AbbVie, Baxter, and Mallinckrodt Pharmaceuticals. She’s built commercial teams and launched several billion-dollar products, including Kaletra®, HUMIRA®, and TriCor®. She has held direct P&L responsibility for over $3B. She has a keen understanding of bringing life-saving drugs to market.
Jim Scully has over 20 years of pharmaceutical experience, where he has acquired a deep knowledge of commercial, clinical development and manufacturing operations. Jim has held leadership roles in Finance, Business Development, Strategic Planning, Business Analytics, Supply Chain and General Management at companies such as Takeda Pharmaceuticals, Astellas Pharmaceuticals, Abbott Laboratories and Walgreens. As Therapeutic Area Head of Global Business Development at Takeda, Jim led or co-led transactions resulting in NPV creation in excess of $2 billion.
Brandon Kashfian has over 20 years of life science sector experience with demonstrated leadership in identification, evaluation, and acquisition of pharmaceutical assets. His pharmaceutical experience includes executive positions at H. Lundbeck, Ovation Pharmaceuticals, Novartis, and Pfizer. Prior to the pharmaceutical industry he invested in life science and medical device companies with William Blair Capital Partners and was an investment banker with JPMorgan Chase.
Steve O’Sullivan has over 25 years of pharmaceutical legal experience. He most recently served as Pfizer’s Asst. General Counsel.
Steve has extensive expertise in pharmaceutical pricing, anti-trust, corporate, and litigation matters. Prior to Pfizer, Steve served as General Counsel and Senior Vice President at Pharmacia and Associate General Counsel at Searle.
John Ellis II has 30 years of medical device, biologic and pharmaceutical experience. He has held leadership roles of increasing responsibility in sales, national accounts, strategy and market access with large public and small private companies. His experience spans American Cyanamid, DeRoyal, Baxter/Baxalta, Mallinckrodt and BioCare. He’s built sales and national account teams launching multiple new products within the medical device, biologics and pharmaceutical industries.
Dr. Somberg is Professor of Medicine and Pharmacology at Rush University School of Medicine and director of the graduate school’s Division of Clinical Research and Therapeutics. Dr. Somberg has served as the principal investigator in more than 100 Phase I, II and III clinical trials, with extensive experience in anti-arrhythmic pharmacology. He serves as a member of the Circulatory Device FDA Advisory Committee, editor of the American Journal of Therapeutics, associate editor of the journal Cardiology and sits on the editorial board of the American Journal of Cardiology.
B. Woun Seo, PhD has 20+ years of pharmaceutical experience in clinical development and medical affairs. His experience spans from small, medium, and large pharma companies, including Searle, Unimed, Solvay, AbbVie, and Pinnacle. Prior to joining the pharmaceutical industry, Woun earned his Ph.D. at the University of Illinois, Urbana campus in Neuroscience, specifically in neuropharmacology. Over the years, Woun has authored multiple peer-reviewed publications and abstracts at national/international meetings.
Scott Gaito brings to AltaThera extensive experience in the pharmaceutical commercial arena. Over the course of more than two decades, he has held positions of increasing responsibility in the fields of pharmaceutical sales management, sales training and commercial operations. His prior experience includes key commercial roles with Endo Pharmaceuticals, Exeltis Pharmaceuticals, Bayer Healthcare and Organon BioSciences. Scott has successfully built and led teams through multiple product launches, across various commercial settings throughout the industry.
Mr. Johnson is a member of the Company’s Board of Managers, appointed by a majority of the Common Unitholders, and serves as Chairman. In addition, Mr. Johnson is the Chairman of the Company’s Compensation Committee. Mr. Johnson has over 30 years of experience in a variety of general management, operations, sales management, business development, and marketing positions at large corporations, including serving as General Manager of a division of Honeywell, and several start-up organizations. He has consulted with companies in the durable medical equipment, consumer, and pharmaceutical industries. He is an Executive Partner with WISC Partners, a venture capital firm that takes active board positions, primarily in the fields of healthcare, healthcare IT, and IT. As a direct investor, he has invested in medical device, durable medical equipment, SaaS, and real estate partnerships. Craig earned his Bachelors of Business Administration in Marketing and Management from the University of Wisconsin-Madison and his Masters in Business Administration in Marketing from DePaul University. He is Six Sigma certified and served as a Reserve Officer in the Armed Forces.
Mr. Kopko is a member of the Company’s Board of Managers, as a designee by certain Preferred Unitholders. In addition, Mr. Kopko serves on the Company’s Compensation Committee and is the chairman of the Company’s Audit Committee. Mr. Kopko has over thirty-eight (38) years of legal experience in the areas of corporate, securities, corporate governance and transactional law, representing publicly traded and privately owned companies. Since January 1990, Mr. Kopko has been a partner at McBreen & Kopko LLP, a law firm based in Chicago, Illinois. Mr. Kopko is the Managing Director of Neltjeberg Bay Enterprises LLC, a merchant banking and business consulting firm located in the United States Virgin Islands. Mr. Kopko is also a principal owner and director of Mercury Air Group, Inc., an aviation services holding company providing cargo, fuel and military services in thirty (30) countries through its ten (10) whollyowned subsidiaries. Mr. Kopko has been a member of the board of directors of Sonic Foundry, Inc. since December 1995. Mr. Kopko received a B.A. in Economics, Phi Beta Kappa, magna cum laude, from the University of Connecticut, his J.D. from the University of Notre Dame Law School, where he was an editor of the Notre Dame Law Review, and an M.B.A., High Honors, from the University of Chicago, Booth School of Business.
Mr. Nisenboim is a member of the Company’s Board of Managers, as a designee of certain Preferred Unitholders. For over 30 years, Mr. Nisenboim has been active investing and participating with venture capital groups and investors in early stage investments, including current Preferred Unitholders, and other investors who are expected to invest in this offering. Since March 2017, he has been an advisory board member in Honor Capital, a privately-owned company in the business of insurance premiums financing. He is also an advisory board member of United Oilfield Services LLC and Alceyone Life Sciences, Inc., a start- up medical device company developing brain catheters for central nervous system diseases. Since June 2010 he has been an advisory board member of Relief Band Medical Technology, a medical device company start-up. He also served as an advisory board member of All Around Roustabout, LLC from 2014 until September 2016 when it transferred its equity to its senior lender in lieu of foreclosure. Roustabout is a greenfield operation in the Bakken shale and originated a Blowout Prevention Testing business and oilfield downhole float equipment and tools business.
Brandon Kashfian has over 20 years of life science sector experience with demonstrated leadership in identification, evaluation, and acquisition of pharmaceutical assets. His pharmaceutical experience includes executive positions at H. Lundbeck, Ovation Pharmaceuticals, Novartis, and Pfizer. Prior to the pharmaceutical industry he invested in life science and medical device companies with William Blair Capital Partners and was an investment banker with JPMorgan Chase.
Jodi Devlin has 30 years of pharmaceutical experience. She has held executive-level roles at large pharmaceutical companies and start-ups. Her expertise spans Abbott /AbbVie, Baxter, and Mallinckrodt Pharmaceuticals. She’s built commercial teams and launched several billion-dollar products, including Kaletra®, HUMIRA®, and TriCor®. She ha held direct P&L responsibility for over $3B. She has a keen understanding of bringing life-saving drugs to market.
Kathryn has been active with young, growing health care companies for over 20 years. She has helped build value as an advisor, management, board member and investor. Kathryn spent eleven years as a principal at the Illinois Emerging Technologies Funds, an early-stage venture capital fund focused on investing in businesses based on cutting edge technologies. She currently serves as the Chief Business Officer of Diagnostic Photonics, one of her venture investments. Previously, she served as the Chief Administrative and Finance Officer, Quark Pharma, Inc., a venture-backed biotechnology company, and spent fourteen years as an investment banker in health care.
Steve O’Sullivan has over 25 years of pharmaceutical legal experience. He most recently served as Pfizer’s Asst. General Counsel.
Steve has extensive expertise in pharmaceutical pricing, anti-trust, corporate, and litigation matters. Prior to Pfizer, Steve served as General Counsel and Senior Vice President at Pharmacia and Associate General Counsel at Searle.
Dr. Bunch is Director of Adult Electrophysiology at Intermountain Medical Center and is the Director for Heart Rhythm Services for Intermountain Healthcare Network. He also serves as Associate Clinical Professor (Affiliated) at Stanford University School of Medicine. He completed residency and two fellowships in cardiovascular medicine and cardiac electrophysiology at the Mayo Clinic and served as Assistant Professor of Medicine at the Mayo Clinic. He is on the editorial boards of numerous journals, including the Heart Rhythm Journal, Journal of Cardiovascular Electrophysiology, Journal of the American College of Cardiology: Clinical Electrophysiology, Heart, and the American Heart Journal. Dr. Bunch was the largest U.S. enroller in the pivotal CABANA (Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation) clinical study, published in 2018.
Dr. Milan is the Chief Scientific Officer of the Leducq organization. Previously, he served as Assistant Professor of Medicine at the Massachusetts General Hospital (MGH) and Harvard Medical School, doing clinical work as well as research focused on the molecular basis of cardiac arrhythmias using zebrafish and stem cell models . He trained at Harvard Medical School and conducted his residency in Internal Medicine at the Brigham and Women’s Hospital, followed by fellowships in Cardiology and Cardiac Electrophysiology at MGH.
Dr. Perry is Director of Electrophysiology, Professor of Pediatrics and Affiliate Professor of Bioengineering at the University of California San Diego and Rady Children’s Hospital. He served on the Editorial Board of Heart Rhythm, is a past President of the Pediatric and Congenital Electrophysiology Society (PACES) and is on the Medical Advisory Board of the Sudden Arrhythmia Death Syndrome (SADS) Foundation.
With a leadership team experienced in the acquisition and launch of specialty products, AltaThera is uniquely positioned to provide a portfolio of specialty therapeutics to hospitals.
Often, our acquisition targets are specialty products that we believe can best maximize efficiencies, safety, and patient convenience, such as our first product, an antiarrhythmic drug.
AltaThera was recently selected by the FDA for a new regulatory program. This program allows for an accelerated pathway to develop new dosing for adult atrial fibrillation.
